Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E47 - What does the next year hold for the NAFLD metabolic disease link?

S3-E47 – What does the next year hold for the NAFLD metabolic disease link?

Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.

SurfingNASH.Com is honored to have the following sponsors

Would you like to participate ask a question join the surfers in our next episode?

S3-E43.1 – Combination Agents for Fibrotic Regression

In Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The theme of the episode is to explore the role of combination agents for NASH therapy over time. This opening conversation focuses on the design and execution of the triple-agent study, and how it may contribute to fibrotic regression.

S3-E43 – Combination Agents: A Cornerstone Of Future NASH Therapy?

Naim Alkhouri and Mazen Noureddin join the Surfers to discuss the future role of Combination Agents with NASH therapy, stemming from their recently published article, Safety and efficacy of combination therapy with semaglutide,cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The conversation focuses more broadly on the benefits and future of combination therapies for NASH patients.

S3-E42.4 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami and talks about educating on liver outcomes. Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan provide their thoughts on education and social resources within the framework of developing a NAFLD pathway.

S3-E42.3 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami to talk about patient empowerment with Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan. The group explores measuring pathways and changing healthcare dynamics through digitization and technology.

S3-E42.2 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this segment, the role of allied health professionals and patient empowerment is discussed in the context of developing a Sustainable Development Goal Framework for NAFLD.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

Experience Nudge Learning!
Interested in a new way of learning?